Last reviewed · How we verify
BOW015
BOW015 is a biosimilar of a biologic therapeutic targeting a specific disease pathway, designed to provide equivalent efficacy and safety to its reference product.
At a glance
| Generic name | BOW015 |
|---|---|
| Also known as | infliximab-EPIRUS |
| Sponsor | Epirus Biopharmaceuticals (Switzerland) GmbH |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a biosimilar in development by Epirus Biopharmaceuticals, BOW015 is engineered to match the molecular and functional characteristics of an approved biologic drug. Biosimilars undergo rigorous comparative clinical and nonclinical testing to demonstrate similarity in safety, purity, and potency to the reference biologic, enabling therapeutic equivalence while potentially offering cost advantages.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BOW015 CI brief — competitive landscape report
- BOW015 updates RSS · CI watch RSS
- Epirus Biopharmaceuticals (Switzerland) GmbH portfolio CI